Mobia Medical (MOBI) director adds to stake with August share purchases
Rhea-AI Filing Summary
Mobia Medical, Inc. director Casey M Tansey reported open-market purchases of 68,559 shares of common stock over three days in August 2026. Transactions included 35,572 shares on August 13 at a weighted average price of $11.5073, 15,821 shares on August 14 at weighted average and fixed prices, and 17,166 shares on August 17 at a weighted average price of $11.8509. Footnotes state that several reported prices are weighted averages based on multiple trades within disclosed price ranges. The Rule 10b5-1 checkbox was not marked as an affirmatively adopted trading plan.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 68,559 shares
Net Buy
4 txns
Insider
Tansey Casey M
Role
Director
Bought
68,559 shs ($797K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F3 | 17,166 | $11.8509 | $203K |
| Purchase | Common Stock F2 | 15,721 | $11.65 | $183K |
| Purchase | Common Stock | 100 | $12.53 | $1K |
| Purchase | Common Stock F1 | 35,572 | $11.5073 | $409K |
Holdings After Transaction:
Common Stock — 301,891 shares (Direct)
Footnotes (3)
- F1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.33 to $11.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.42 to $12.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.675 to $12.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Key Figures
Total shares purchased: 68,559 shares
Shares purchased on August 13, 2026: 35,572 shares
Weighted average price on August 13, 2026: $11.5073 per share
+2 more
5 metrics
Total shares purchased
68,559 shares
Aggregate net-buy across four open-market transactions in August 2026
Shares purchased on August 13, 2026
35,572 shares
Common Stock, open-market purchases at weighted average price
Weighted average price on August 13, 2026
$11.5073 per share
Price based on multiple trades from $11.33 to $11.685
Shares purchased on August 14, 2026
15,821 shares
Includes 15,721 shares at weighted average $11.65 and 100 shares at $12.53
Shares purchased on August 17, 2026
17,166 shares
Common Stock, open-market purchases at weighted average $11.8509
Key Terms
weighted average price, open market or private transaction, Rule 10b5-1
3 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open market or private transaction financial
"transaction_code_description: Purchase in open market or private transaction"
Rule 10b5-1 regulatory
"The filing’s Rule 10b5-1 checkbox is not marked as affirmed"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
What insider transactions did MOBI director Casey M Tansey report in this Form 4?
Casey M Tansey reported 68,559 shares of Mobia Medical, Inc. (MOBI) common stock purchased in open-market transactions over three days in August 2026, with multiple trades executed at various prices within disclosed ranges.
Were the MOBI insider purchases by Casey M Tansey made under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmed under a trading plan. Footnotes describe weighted average pricing but do not state that the transactions were executed pursuant to a Rule 10b5-1 trading arrangement.
AI-generated analysis. How Rhea-AI works. Not financial advice.